Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OTX1-1
- Development stage
- Preclinical
- Lead developer
- OssiFi
- Modality
- Small Molecules
- Administration
- Implant
01
Overview
OTX1-1 is an investigational small molecule sclerostin inhibitor being developed by OssiFi. It is designed as a localized antisclerostin therapy delivered via an orthopedic implant coating. By inhibiting sclerostin, a negative regulator of bone formation, OTX1-1 aims to promote localized bone formation and enhance osseointegration and integration strength around orthopedic implants, addressing low bone density and improving orthopedic instrumentation outcomes.
02
Targets
SOST (Sclerostin)
Beyond the preview
Go deeper on OTX1-1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OTX1-1.